Overview

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Status:
Terminated
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
This prospective, two-site, two-arm, randomized, single-blind, placebo-controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 84 consecutive days by sexually active women. The primary objective is to assess the safety of TDF vaginal rings when used continuously for 84 days by healthy, HIV-uninfected, sexually active women, as compared with a placebo vaginal ring.
Phase:
Phase 1
Details
Lead Sponsor:
Albert Einstein College of Medicine of Yeshiva University
Marla Keller
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Tenofovir